Lu-177 DOTATATE + Cabozantanib in NETs
Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors
CLINICALTRIALS.GOV IDENTIFIER: NCT05249114
DRUG/TREATMENT: Cabozantinib with Lu-177 DOTATATE administration IV
PHASE: 1b
STATUS: Recruiting
SPONSORS: Providence Health & Services
COLLABORATORS: Advanced Accelerator Applications SA & Exelixis
Dr. Kennecke discusses Cabozantinib with Lu-177 DOTATATE
DESCRIPTION:
The phase I objective of this study is to establish the maximal tolerated dose (MTD) of cabozantinib in 20 mg, 40 mg and 60 mg dose escalation cohorts in combination with Lu-177 dotatate at a standard dose of 7.4 GBq in four (4) 8-week cycles followed by continuation cabozantinib.
READ:
2023 NANETS Abstract, 10/12/2023
For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here.
PRINCIPAL INVESTIGATOR:Â
Hagen Kennecke, MD, MHA
Providence Health & Services
CONTACT:
Mary McCormick, RN
EMAIL: mary.mccormick@providence.org
PHONE: 503-215-9570